Zoetic Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
as on 17-12-2024
- Paid Up Capital ₹ 0.30 M
as on 17-12-2024
- Company Age 27 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 45.39%
(FY 2022)
- Profit 19.50%
(FY 2022)
- Ebitda 43.53%
(FY 2022)
- Net Worth 8.52%
(FY 2022)
- Total Assets 0.76%
(FY 2022)
About Zoetic Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.30 M, as per Ministry of Corporate Affairs (MCA) records.
Shanmugasundaram Muthukumarsamy and Ramaiyah Ramesh serve as directors at the Company.
- CIN/LLPIN
U24231TN1997PTC037687
- Company No.
037687
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Mar 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Zoetic Formulations?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramaiyah Ramesh  | Managing Director | 10-Mar-2007 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shanmugasundaram Muthukumarsamy | Director | 10-Mar-2007 | Current |
Financial Performance of Zoetic Formulations.
Zoetic Formulations Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 45.39% increase. The company also saw a substantial improvement in profitability, with a 19.5% increase in profit. The company's net worth moved up by a moderate rise of 8.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zoetic Formulations?
In 2022, Zoetic Formulations had a promoter holding of 41.67% and a public holding of 58.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zeta Laboratories Private LimitedActive 19 years 7 monthsShanmugasundaram Muthukumarsamy and Ramaiyah Ramesh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zoetic Formulations?
Zoetic Formulations has a workforce of 0 employees as of May 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zoetic Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zoetic Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
